Concord Asset Management (Virginia)’s Vertex Pharmaceuticals VRTX Stock Holding History

Concord Asset Management (Virginia)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,380	Closed	-$1.66M	–	204
2025 Q1	$1.66M	Sell	3,380 -188	-5%	-$87.6K	0.37%	70
2024 Q4	$1.44M	Buy	3,568 +741	+26%	+$343K	0.32%	69
2024 Q3	$1.31M	Buy	2,827 +502	+22%	+$241K	0.3%	68
2024 Q2	$1.09M	Buy	2,325 +773	+50%	+$336K	0.27%	70
2024 Q1	$649K	Buy	1,552 +407	+36%	+$172K	0.17%	92
2023 Q4	$466K	Buy	1,145 +484	+73%	+$179K	0.14%	101
2023 Q3	$230K	Buy	+661	New	+$231K	0.08%	117

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Concord Asset Management (Virginia)'s VRTX Position: Q2 2025 in Review

Concord Asset Management (Virginia) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 3,380 shares — an estimated $1.66M sold.

Concord Asset Management (Virginia) first reported a position in VRTX in Q3 2023 and held it in 7 quarters. The position peaked at $1.66M in Q1 2025. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Concord Asset Management (Virginia) reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Concord Asset Management (Virginia) sold 3,380 Vertex Pharmaceuticals shares in Q2 2025, an estimated $1.66M.
Concord Asset Management (Virginia) first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 7 quarters.
Concord Asset Management (Virginia)'s Vertex Pharmaceuticals position peaked at $1.66M in Q1 2025.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Concord Asset Management (Virginia)'s 13F filing for Q2 2025, filed 25 Jul 2025.